Viatris Launches Third Oncology Biosimilar Abevmy® (bevacizumab)

Viatris Inc. announced that Abevmy® is now available in Canada. Abevmy, is a biosimilar to Roche’s Avastin® (bevacizumab) and has been authorized for use by Health Canada across four oncology indications.

Abevmy is the fourth biosimilar to be offered by Viatris in Canada and the third to support patients living with cancer. Abevmy is also the third oncology biosimilar included in the Viatris AdvocateTM PSP offering additional support services to patients and their caregivers.

For more information on Abevmy,  connect with your Viatris representative or contact Viatris Customer Service at 1-800-575-1379.